Methicillin-resistant Staphylococcus aureus: an update for the dermatologist, Part 3: Clinical management.
Methicillin-resistant Staphylococcus aureus (MRSA) is increasingly becoming a major source of systemic infection in the community and healthcare settings. The disease is responsible for deaths among individuals without known risk factors and presents a therapeutic challenge for clinicians because of the bacteria's complex epidemiology and mechanisms of antibiotic resistance. Furthermore, the skin and soft tissue are the most commonly infected organs. Consequently it is necessary for the dermatologist to have an understanding of the management of the condition to prevent lethal manifestations and further spread to the community. This 4-part review covers the epidemiology, pathogenesis, and management of the disease, including new treatment options. The third part of the review will focus on the clinical management of MRSA infection.
Kil
Erin H
EH
Department of Dermatology, St. Luke's-Roosevelt Hospital Center, New York, New York, USA.
Heymann
Warren R
WR
Weinberg
Jeffrey M
JM
D000081:Acetamides / Q000627:therapeutic use; D000465:Algorithms; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002981:Clindamycin / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000188:drug therapy*; D006801:Humans; D000069349:Linezolid; D016106:Methicillin Resistance; D023303:Oxazolidinones / Q000627:therapeutic use; D013207:Staphylococcal Skin Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects; D013752:Tetracycline / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D002981:Clindamycin; D014640:Vancomycin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D013752:Tetracycline; D000069349:Linezolid